CSPC Jiangzhong Pharmaceutical Co., Ltd. -B (09966): JSKN022 IND application officially accepted by CDE.

The Smart Financial News APP reported that CStone Pharmaceuticals-B (09966) announced that the company's independently developed Programmed Death Ligand 1 (PD-L1)/Integrin v6 bispecific antibody-drug conjugate (ADC) JSKN022 has officially been accepted for clinical trial application by the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE). The company plans to conduct the first human clinical study of JSKN022 for the treatment of advanced malignant solid tumors.